is required for a,-adrenergic agonist binding.
INTRODUCTION
Adrenergic regulation of adenylate cyclase can be either stimulatory or inhibitory. Agonistinduced attenuation of adenylate cyclase activity has been demonstrated in several systems including those containing az-adrenergic [ 11, muscarinic [2] and opiate receptors [3] . This effect requires a guanyl nucleotide regulatory protein, pi [4] . Agonist binding to inhibitory receptors may also involve an interaction with Ni, but this is less well characterized. GTP analogs decrease the affinity of crz-adrenergic agonist binding with no decrease in antagonist binding [5, 6] or even an increase [7] .
Abbreviations: IAP, islet-activating protein (pertussis toxin); Ni, inhibitory guanine nucleotide-binding protein; N,, stimulatory guanine nucleotide-binding protein; PAC, p-aminoclonidine; P/Y, ratio of specifically bound 3 nM [3H]PAC/10 nM [jH]yohimbine; TM, buffer containing 50 mM Tris-Cl, pH 7.6, 10 mM MgC12; TME, TM buffer supplemented with 1 mM EGTA; UK 14,304, 5-bromo-6-N-[2-(4,5-dihydroimidazolyl)]quinoxaline A similar reduction of agonist binding has also been demonstrated for membranes from cells treated with pertussis toxin [8-lo] . Because of these observations, it has been hypothesized that inhibitory agonist binding to human platelet cuz-receptors requires Ni.
Citri and Schramm reported a selective inactivation of the stimulatory guanine nucleotide regulatory protein, N,, and the catalytic subunit of adenylate cyclase, C, after treatment of turkey erythrocyte membranes with alkaline buffer [ll, 121. Here, we report a selective abolition of highaffinity az-agonist binding without significant inactivation of antagonist binding following pretreatment of human platelet membranes under alkaline conditions. This effect is correlated with a parallel decrease in pertussis toxin-catalyzed [32P]ADP-ribosylation of Ni. These observations provide additional evidence that high-affinity agonist binding to platelet a*-adrenergic receptors requires a functional Ni protein and provides a new tool for studying this interaction. A preliminary report of this work has been presented in abstract form [13] . 
Purification of platelet membranes
Purified human platelet membranes were prepared by the method of Neubig and Szamraj [15] and stored at -70°C for up to 6 weeks prior to use.
Alkaline treatment
Platelet membranes were thawed, homogenized with 5 strokes in a Potter-Elvehjem homogenizer, and diluted 20-fold with 50 mm sodium phosphate (pH 7.6-12.0). After incubation on ice for 1 h, membranes were collected by centrifugation at 145 000 x g for 30 min and resuspended in buffer A (50 mM Tris-Cl, 10 mM MgC12, 1 mM EGTA, pH 7.6) for binding assays and pertussis toxin labelling.
Binding assays and pertussis toxin labelling
Reagents 
RESULTS
Incubation of purified platelet membranes at a pH up to 11 .O for 1 h did not affect binding of 10 nM [3H]yohimbine; however, at pH 11.5-12, there was a partial reduction in binding ( fig.1 ). Highaffinity agonist binding as measured by 3 nM ['H]PAC was also unaffected to pH 11 .O, but was completely lost at pH 11.5 or greater ( fig. 1 ). This effect of pH was complete in less than 30 min (not shown); consequently, 1 h was used as a standard incubation condition.
Equilibrium binding curves for [3H]PAC and r3H]yohimbine were performed with membranes pretreated in 50 mM phosphate buffer, pH 7.6 (control) and pH 11.5 (pH 11.5 membranes). There was no significant change in & and only a slight reduction in Bmax for yohimbine binding to pH 11.5 membranes ( fig.2A ). Analysis using SCAFIT showed the best fit to a one-site model with a Kd and Bmax for control membranes of To assess the effect of alkaline treatment on the inhibitory guanine nucleotide-binding protein, pertussis toxin-catalyzed
[32P]ADP-ribosylation of the a-subunit (M, 41000) of Ni was used to quantitate amounts of that protein in cholate extracts from membranes pretreated at pH ranging from 7.6 to 12.0 ( fig.3 ). There is a gradual decrease of approx. 50% in the amount of labelling of the Ni a-subunit from pH 7.6 to 11 .O. At pH 11.5 a nearly complete abolition of labelling occurs. This sharp decrease parallels the decrease observed in high-affinity agonist binding. In some preparations of pH-pretreated membranes, we observed an increase in labelling at pH 10.-O, however, in all cases, there was a decrease for pH 11 .O or greater. Selective reduction of a2-agonist binding has also been reported for the reversible reagents sodium [ 171 and GppNHp [14] and irreversible reagents N-ethylmaleimide [ 18,191, chymotrypsin [20] , heat [19] and pertussis toxin [g-lo] . Only for the latter is the mechanism known to involve effects on the inhibitory guanine nucleotide-binding protein, Ni. The parallel loss of pertussis toxin substrate and a2-agonist binding between pH 11 .O and 11.5 suggests that inactivation of Ni results in the selective loss of high-affinity agonist binding. Final proof of this mechanism would require 324 reconstitution of high-affinity agonist binding with purified Ni. This type of experiment has recently been performed using solubilized muscarinic receptors [21] .
Although the complete inactivation of Ni parallels the loss of [3H]PAC binding, in each experiment there was some decrease in pertussis toxin substrate at pH 10.5-11 without loss of agonist binding. It is possible that alkaline treatment affects the activity of Ni as a pertussis toxin substrate (e.g. by dissociating the subunits) without affecting its ability to couple to receptors. Another likely explanation can be found in the fact that there is a 25-lOO-fold excess of Ni protein over &2-receptors in platelet membranes [14] . Consequently, inactivation of 50-80% of the Ni would still leave more than enough to couple to cyz-adrenergic receptors' (see Note, p. 323).
Recently, Childers and co-workers [22, 23] studied the effects of acid (pH 4.5) treatment of brain membranes on opiate receptors. Control agonist binding was apparently not changed but the sensitivity to guanine nucleotides was increased. Also, opiate receptor-mediated inhibition of adenylate cyclase was increased. The relation of these observations to our present findings is not clear. Effects of alkaline treatment on receptormediated inhibition of adenylate cyclase in our system cannot be determined because catalytic activity is completely inactivated at pH 11 (not shown).
Our data provide additional evidence for the role of the guanine nucleotide-binding protein, Ni, in promoting high-affinity az-agonist (and partial agonist) binding. Alkaline treatment should prove a useful tool in studying receptor-Ni interactions.
